Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CoVacHGMix (4c75ab)
- Development stage
- Unknown
- Lead developer
- Ankara City Hospital Bilkent
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CoVacHGMix is a non-replicating Type 5 adenoviral vector vaccine developed by Ankara City Hospital Bilkent for the prevention of COVID-19. The vaccine is a multi-component formulation containing equal amounts of four distinct adenoviral vector components: CoVacHGA1320, CoVacHGB420, CoVacHGC720, and CoVacHGD1480. It is designed to deliver SARS-CoV-2 antigens to host cells to elicit a protective immune response. Clinical development has proceeded through a Phase I adaptive design study in healthy volunteers aged 18-59 years, evaluating safety and immunogenicity at two dose levels (5x10^10 and 1x10^11) administered intramuscularly in a two-dose regimen on days 0 and 28.
- Other names
- adenoviral vector vaccine-Ankara City Hospital Bilkent-COVID-19
02
Targets
SARS-CoV-2 spikeNeuraminidaseCXADR (Coxsackievirus and adenovirus receptor)
Beyond the preview
Go deeper on CoVacHGMix (4c75ab).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CoVacHGMix (4c75ab).